Thousand Oaks Biopharmaceuticals

Thousand Oaks Biopharmaceuticals (also known as TOBio and 澳斯康生物), founded in 2017 by Dr. Shun Luo, operates as an integrated Chemistry, Manufacturing, and Controls (CMC) solution provider for the biopharmaceutical industry. Dr. Luo, who holds a Ph.D. in Molecular Immunology from Virginia Tech, brought nearly 30 years of experience to the company, including leadership roles at global pharmaceutical firms like Genentech, Amgen, and JRH Biosciences. He established the company with the vision of making high-quality biologics accessible and affordable globally.

The company's business is structured around two primary segments: biopharmaceutical Contract Development and Manufacturing Organization (CDMO) services and the production of cell culture media. The CDMO division offers a comprehensive, one-stop service that covers the entire lifecycle of a biologic drug, from initial DNA sequence and cell line development to process development, clinical material supply, and full-scale commercial manufacturing. This includes extensive experience with monoclonal antibodies, bispecific antibodies, antibody-drug conjugates (ADC), and fusion proteins. Their facilities are designed to meet the regulatory standards of the US FDA, EU EMA, and China's NMPA.

The second core business is the development and sale of cell culture media, a critical raw material for biopharmaceutical production. This segment operates through its subsidiary, JSBio (formerly Gansu Jianshun), which Dr. Luo founded in 2011 to break the market's reliance on foreign suppliers. JSBio has become a leading domestic brand for serum-free cell culture media in China. This vertical integration of a key raw material provides the company with a significant operational advantage, allowing it to control costs and ensure a stable supply chain for its CDMO clients. The company generates revenue through service fees for its end-to-end CDMO solutions and the direct sale of its cell culture media products. Recent developments include the passing of an audit by a European Union Qualified Person (QP) for its ADC manufacturing site in Shanghai in late 2025, certifying its compliance with EU GMP standards.

Keywords: CDMO, CMC services, biopharmaceutical manufacturing, cell culture media, contract development, biologics, monoclonal antibodies, antibody-drug conjugates, ADC, process development, GMP manufacturing, bioprocessing, Shun Luo, JSBio, serum-free media, IND filing, BLA submission, clinical manufacturing, commercial manufacturing, pharmaceutical services, biotech outsourcing, recombinant proteins, vaccine production, cell therapy